Evidence map›Paper›PMID 41674845›Full record

ArticleResearch square2026

Prioritizing Therapeutic Targets for Interstitial Lung Disease: A Causal Mediation Analysis.

Justin Oldham, Philip Molyneaux, Manoj Maddali, Chad Newton, John Kim, Sam Konkol, Janelle Pugashetti, Gabrielle Liu, Gillian Goobie, Ayodeji Adegunsoye and 25 more

Abstract readPreprint
In one paragraph

Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors.

Justin OldhamUniversity of Michigan.
Philip MolyneauxNational Heart and Lung Institute, Imperial College London.ORCID https://orcid.org/0000-0003-1301-8800
Manoj MaddaliPiedmont Healthcare.
Chad NewtonUniversity of Texas Southwestern.ORCID https://orcid.org/0000-0001-5256-9029
John KimUniversity of Virginia.ORCID https://orcid.org/0000-0002-8887-150X
Sam KonkolUniversity of Virginia.
Janelle PugashettiUniversity of Michigan.
Gabrielle LiuUniversity of California at Davis.
Gillian GoobieUniversity of British Columbia.
Ayodeji AdegunsoyeUniversity of Chicago.
Shwu-Fan MaUniversity of Virginia.ORCID https://orcid.org/0000-0002-3058-9480
Drew BornsteinUniversity of Michigan.
Susan MurrayUniversity of Michigan.
Louise WainUniversity of Leicester.ORCID https://orcid.org/0000-0003-4951-1867
Gauri SainiUniversity of Nottingham.
Iain StewartImperial College London.
Simon JohnsonUniversity of Nottingham.ORCID https://orcid.org/0000-0002-9837-2763
Gisli JenkinsNational Heart and Lung Institute, Imperial College.
Mary StrekUniversity of Chicago.
Angela LinderholmUniversity of California at Davis.
Ching-Hsien ChenUniversity of California Davis.ORCID https://orcid.org/0000-0002-4211-9988
William FahyGlaxoSmithKline (United Kingdom).
Rachel ZemansUniversity of Michigan-Ann Arbor.ORCID https://orcid.org/0000-0003-3537-9869
Dinesh KhannaUniversity of Michigan.ORCID https://orcid.org/0000-0003-1412-4453
Christopher RyersonUniversity of British Columbia.
Kevin FlahertyUniversity of Michigan.
Madathilparambil SureshUniversity of Michigan-Ann Arbor.
Anna-Maria Hoffmann-VoldOslo University Hospital.
Toby MaherRoyal Brompton Hospital.ORCID https://orcid.org/0000-0001-7192-9149
Christine GarciaColumbia University Medical Center.ORCID https://orcid.org/0000-0002-0771-1249
Paul WoltersUniversity of California, San Francisco.ORCID https://orcid.org/0000-0002-3108-6164
Fernando MartinezUniversity of Massachusetts Chan Medical School.ORCID https://orcid.org/0000-0002-2412-3182
Imre NothUniversity of Virginia School of Medicine.
Jennifer A SmithDepartment of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI, USA.ORCID https://orcid.org/0000-0002-3575-5468

Funding

POSTDOCTORAL TRAINING IN MEDICAL INFORMATION SCIENCEST15LM007033 · NLM · STANFORD UNIVERSITY · PI SYLVIA KATINA PLEVRITIS · 1985 to 2026
$25.5M
Pulmonary Fibrosis and Telomerase DysfunctionR01HL093096 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI GARCIA, CHRISTINE KIM · 2009 to 2024
$6.9M
Lung Remodeling Mediated by Telomere Dysfunction in Alveolar Type II CellsR01HL139897 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Paul j WOLTERS · 2018 to 2026
$5.5M
Proteomic Profiling of Idiopathic Pulmonary Fibrosis Progression TrajectoryR01HL169166 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Justin M Oldham · 2023 to 2026
$2.7M
Prognostic Biomarker Development in Progressive Fibrosing Interstitial Lung DiseaseR01HL166290 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Justin M Oldham · 2024 to 2026
$2.2M
Immune crosstalk in lung injury and fibrosisR35HL176572 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Bethany B. Moore · 2025 to 2026
$2.1M
1/2 Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases studyUG3HL145266 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI MARTINEZ, FERNANDO J, NOTH, IMRE · 2019 to 2019
$977k
Molecular Markers of Idiopathic Pulmonary Fibrosis ProgressionK23HL148498 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI NEWTON, CHAD ALAN · 2020 to 2024
$891k
Role of polyunsaturated fatty acids in pulmonary fibrosisK23HL150301 · NHLBI · UNIVERSITY OF VIRGINIA · PI KIM, JOHN S · 2021 to 2025
$858k
Improving Pulmonary Fibrosis Classification with Genomics Informed Phenotypic ClustersK23HL146942 · NHLBI · UNIVERSITY OF CHICAGO · PI ADEGUNSOYE, AYODEJI · 2020 to 2024
$810k
A Multi-Dimensional Signature to Predict Treatment Failure in Patients with Connective Tissue Disease-Associated Interstitial Lung DiseaseK23HL171871 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Janelle Vu Pugashetti · 2025 to 2026
$392k
NHLBI NIH HHS K23 HL146942NHLBI NIH HHS K23 HL148498NHLBI NIH HHS K23 HL150301NHLBI NIH HHS K23 HL171871NHLBI NIH HHS L30 HL181822NHLBI NIH HHS R01 HL093096NHLBI NIH HHS R01 HL139897NHLBI NIH HHS R01 HL166290NHLBI NIH HHS R01 HL169166NHLBI NIH HHS R35 HL176572NHLBI NIH HHS UG3 HL145266NLM NIH HHS T15 LM007033
6 · The paper itself

Abstract

Progressive interstitial lung disease (ILD) leads to declining lung function and death. New therapies to treat ILD are urgently needed. Here we performed a secondary analysis of proteomic data from ten ILD cohorts across the United States, Canada, and United Kingdom. Causal mediation analysis was used to estimate the effect of plasma proteins previously linked to organ fibrosis in mechanistic studies (exposure) on survival (outcome) through lung function decline (mediator). Of 102 proteins tested in a discovery cohort (n = 1963), 47 were mediated by declining lung function. Of these 47 proteins, 7 showed sustained mediation in an independent validation cohort (n = 1172). Proteins with the strongest mediated effect were amphiregulin and integrin beta six. Sensitivity analysis showed that results were robust to unmeasured confounding. Here we provide epidemiological evidence implicating seven proteins as potentially causal of progressive ILD. These findings build upon mechanistic studies showing a causal link between these proteins and organ fibrosis, supporting their prioritization for therapeutic consideration.

Indexed as

BiomarkerInterstitial Lung DiseaseMediationProgressive Pulmonary FibrosisProteomics

Identifiers

PMID41674845
PMCPMC12889817

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.